

This is an author produced version of a paper published in Cell biology and toxicology.

This paper has been peer-reviewed and is proof-corrected, but does not include the journal pagination.

Citation for the published paper:

Tallkvist, Jonas., Yagdiran, Yagmur., Danielsson, Louise., Oskarsson, Agneta. (2015) A model of secreting murine mammary epithelial HC11 cells comprising endogenous Bcrp/Abcg2 expression and function. Cell biology and toxicology. Volume: 31, Number: 2, pp 111-120. http://dx.doi.org/10.1007/s10565-015-9298-5.

Access to the published version may require journal subscription. Published with permission from: Springer.

Epsilon Open Archive http://epsilon.slu.se

1	
2	
3	A Model of Secreting Murine Mammary Epithelial HC11 Cells Comprising Endogenous
4	Bcrp/Abcg2 Expression and Function
5	
6	Jonas Tallkvist [*] , Yagmur Yagdiran, Louise Danielsson, Agneta Oskarsson
7	
8	Department of Biomedical Sciences and Veterinary Public Health, Swedish University of
9	Agricultural Sciences, SE-750 07 Uppsala, Sweden
10	
11	
12	
13	
14	
15	Running title: Bcrp/Abcg2 Mediated Transport in Mammary Epithelial Cells
16	
17	
18	
19	
20	*Corresponding author:
21	Jonas Tallkvist
22	Department of Biomedical Sciences and Veterinary Public Health, Swedish University of
23	Agricultural Sciences, SE-750 07 Uppsala, Sweden
24	
25	Phone.: +46 18 673178; Email: Jonas.Tallkvist@slu.se
26	

1 Abstract

2

3 Breast cancer resistance protein (Bcrp/Abcg2) and multidrug transporter 1 (Mdr1/Abcb1) are 4 efflux proteins located in the apical membrane of mammary epithelial cells (MEC). Bcrp is 5 induced in MEC during gestation and lactation, while Mdr1 is down-regulated during 6 lactation. Numerous drugs and toxic compounds are known to be actively secreted into milk 7 by Bcrp, but most chemicals have not been investigated in this respect, emphasizing the need 8 for functional Bcrp studies in an established cell line with secreting mammary epithelial cells. 9 The present study was undertaken to examine expressions of Bcrp and Mdr1 in mammary 10 epithelial HC11 cells, derived from a mid-gestational murine mammary gland. In addition, 11 Bcrp function was assessed by transport experiments with mitoxantrone (MX) in 12 undifferentiated HC11 cells, in HC11 cells subjected to *Bcrp* RNA interference (RNAi) as 13 well as in HC11 cells stimulated to differentiate by treatment with lactogenic hormones. 14 Differentiated HC11 cells organized into alveolar-resembling structures and gene expression of the major milk protein β-casein was induced, whereas undifferentiated cells formed 15 16 monolayers with lower β -case in expression. Bcrp and Mdr1 gene and protein were expressed 17 in both undifferentiated and differentiated HC11 cells. Differentiation of HC11 cells resulted 18 in increased Bcrp protein expression, while Mdr1 gene and protein expressions were reduced. 19 The Bcrp inhibitor elacridar (GF120918) reduced secretion and increased accumulation of 20 MX in both undifferentiated and differentiated HC11 cells. Silencing of the *Bcrp* gene caused 21 an increased accumulation of MX. The results indicate that the HC11 cell model provides a 22 promising tool to investigate transport of potential Bcrp substrates in mammary epithelial 23 cells. 24

- 25
- 26

1 Introduction

2

3 Breast cancer resistance protein (BCRP/ABCG2) is a 72 kDa protein, composed by a single 4 N-terminal ATP binding site followed by six putative transmembrane segments, belonging to 5 the ATP binding cassette (ABC) superfamily of transporters (Doyle et al., 1998). BCRP is 6 situated in the apical membrane of epithelial cells in numerous tissues including the intestine, 7 liver, kidneys and several blood-tissue barriers where it serves to extrude its substrates and by 8 these means limiting availability and systemic exposure (Jonker et al., 2000; Maliepaard et al., 9 2001; Zhang et al., 2004). Furthermore, BCRP is highly expressed in cancer cells where it 10 prevents the uptake of the antineoplastic drug mitoxantrone, diminishing its therapeutic effect 11 (Doyle et al., 1998; Bates et al., 2001). Thus, one important biological function of BCRP in 12 most tissues appears to comprise cellular protection and detoxification.

13

14 BCRP is also expressed in apical membrane of mammary epithelial cells (MEC) which faces 15 the alveolar lumen of the mammary glands (Jonker et al., 2005; Lindner et al., 2013). During 16 gestation and lactation BCRP is upregulated. Although the physiological role for BCRP in 17 MEC is not totally clarified the transporter has been demonstrated to actively efflux vitamin 18 B2 (riboflavin) into milk (van Herwaarden et al., 2007; Vlaming et al., 2009). Furthermore, 19 active secretion of a variety of exogenous BCRP substrates, including human and veterinary 20 drugs, environmental pollutants and other food contaminants, into milk have been 21 demonstrated (Jonker et al., 2005; van Herwaarden et al., 2007; Mealey 2012). Expression 22 and function of BCRP can also be influenced by chemicals. Thus, flavonoids and 23 isoflavonoids, present in many food and feed plants, inhibit BCRP and may thus decrease 24 milk secretion of BCRP substrates (Zhang et al., 2004; Morris and Zhang, 2006). On the other 25 hand, 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (TCDD) and the fungicide prochloraz induce

BCRP in mammary epithelial cells and may increase the milk excretion of BCRP substrates
 (Halwachs et al., 2013).

3

4 The exposure of hazardous compounds via milk in sensitive population groups is of high 5 concern in risk assessment and there is a need for methods to screen for chemicals with active 6 transport into milk and to further investigate the underlying mechanisms. Transfected Madin-7 Darby Canine Kidney II (MDCKII) epithelial cells stably expressing human, bovine and 8 caprine BCRP have been used to identify new BCRP substrates as well as the impact of the 9 common Y581S point mutation in BCRP function (Jonker et al, 2000; Real et al., 2011; 10 Wassermann et al., 2013; Halwachs et al., 2014). However, expression and function of 11 endogenous BCRP in non-tumorigenic mammary epithelial cell lines has not yet been 12 examined. Such a model would be valuable for studies on BCRP expression and function after 13 treatment with xenobiotics.

14

15 HC11 cells are non-tumorigenic mammary epithelial cells derived from the mouse mammary 16 epithelial cell line COMMA-1D collected from the mammary glands of Balb/c mice during 17 mid-gestation (Danielson et al, 1984). The HC11 cells express functional prolactin receptors 18 and have been used as a model to examine the progression of mammary epithelial 19 differentiation to a secreting phenotype (Ball et al., 1988; Marte et al., 1994; Desrivières et al., 20 2003). In addition, the HC11 cell model has been applied to characterize transporters implicated in the flux of zinc, copper, sodium and calcium across the membranes of the 21 22 lactating mammary epithelium (Kelleher and Lönnerdal, 2005, 2006; Boyd and Náray-Fejes-23 Tóth, 2007; Öhrvik et al, 2010; McCormick and Kelleher, 2012; Ross et al., 2013). However, 24 no studies have so far been directed to investigating expression and function of ABC 25 transporters in HC11 cells.

The present study was undertaken to examine endogenous expressions of Bcrp and Mdr1 in
mammary epithelial HC11 cells. In addition, transport experiments with the BCRP substrate
mitoxantrone (MX) were carried out in undifferentiated HC11 cells, in HC11 cells subjected
to *Bcrp* RNAi as well as in HC11 cells stimulated to differentiate by treatment with lactogenic
hormones.

3 *Cells*

HC11 cells of passage 26 was a generous gift from Dr Shannon Kelleher, Department of 4 5 Nutritional Sciences, Pennsylvania State University, USA and was cultured by permission of 6 Dr Bernd Groner, Institute for Biomedical Research, Frankfurt, Germany. The cells were 7 expanded in T75 tissue culture flasks at 37°C in 15 ml of sterile filtered RPMI 1640 medium 8 containing L-glutamin and 25 mM HEPES (Invitrogen) supplemented with 50 µg/ml 9 gentamicin, 5 µg/ml bovine insulin, 10 ng/ml epidermal growth factor (EGF), 7.5% NaHCO3 10 and 10% heat-inactivated foetal bovine serum (FBS) in an atmosphere of 95% air and 5% 11 CO2 in 95% relative humidity. The cell culture medium was changed every 2-3 days and cells between passages 28-33 were harvested at 80-90% confluency. HC11 cells were seeded at a 12 density of 50,000 cells/cm² in 6-well plates and cultured to confluency. Two days 13 14 postconfluency cells were cultured for an additional 24 h in the FBS-containing RPMI 1640 medium described above but without EGF. Differentiation of the HC11 cells was then 15 16 achieved by culturing the cells for 72 h in EGF- and FBS-free RPMI 1640 medium 17 supplemented with1 µg/ml prolactin and 1 µM cortisol as described (Desrivières et al., 2003). 18 Undifferentiated HC11 cells (controls) were cultured in parallel with the FBS- and EGF-19 containing RPMI 1640 medium. To study the cellular organization approximately 800,000 20 cells in a volume of 400 µl were seeded per chamber on slides (Lab-Tec® chamber slide™ 21 system, Nalge Nunc International). In 4 of the 8 chambers on each slide (n=3) the cells were 22 allowed to differentiate for 3 days as described above whereas the other 4 served as undifferentiated controls. The cells were fixed in 4°C acetone for 5 min and then rinsed with 23 24 1XPBS, pH 7.4 prior to nuclei staining with hematoxylin.

1 Quantitative real-time RT-PCR

2 Following incubation of the HC11 cells in either control or differentiating culture medium as 3 described above or transfection medium as described below the cells were rinsed with 1XPBS and the RNA was isolated by applying NucleoSpin[®]RNA II Columns with DNaseI according 4 5 to the instructions of the manufacturer (BD Biosciences). As a quality control of primers used 6 in the real-time RT-PCR with cellular RNA, primers were tested on RNA from mouse 7 mammary gland tissues taken at different lactation stages. HARLAN NMRI-mice were given 8 a standard pellet diet and tap water ad libitum under standard conditions of temperature and 9 light. Animals were killed by cervical dislocation and mammary glands from pregnant 10 (gestation days 13 and 18), lactating (lactation days 2 and 9) and weaning (weaning day 2) 11 mice were rapidly excised, placed in RNAlater (Invitrogen), snap-frozen in liquid nitrogen 12 and stored at -70°C pending isolation of total RNA. Tissues were homogenized in 10 volumes 13 of RA1 buffer as recommended by the manufacturer (BD Biosciences) and RNA isolated with NucleoSpin[®]RNA II Columns with DNaseI as described above. Animal experiments were 14 15 ethically approved (permit no. 2012-15-2934-00587) and carried out in collaboration with Dr Christopher Knight, at the Department of Health and Medical Sciences, University of 16 17 Copenhagen, Denmark. Total RNA from mammary glands was quantitated by use of the 18 RiboGreen protocol with DNase I (Invitrogen) and RNA samples were stored at -70°C until 19 used. Quantitative gene expression was measured by real-time RT-PCR by applying a 20 Rotorgene, RG3000 (Corbett Research) as described (Öhrvik et al., 2010) in the presence of 400 nM forward and reverse primers in a total volume of 12.5 µl (Table 1). 21

22

23 Western Blot

HC11 cells were seeded at a density of 50,000 cells/cm² in a total of 4 separate T75 tissue

25 culture flasks and cultured and differentiated as described above prior to harvesting by

1 trypsination and homogenization of the obtained cell pellet in 5 volumes of RIPA-lysis buffer. 2 HC11 cells in 2 T75 flasks were differentiated as described above while the cells in the other 3 2 flasks served as undifferentiated controls. The homogenization of the HC11 cells was 4 carried out in 1.5 ml Eppendorf tubes by thorough pipetting. Homogenates were incubated on 5 ice for 30 min and then centrifuged at 16,000Xg for 30 min at 4°C and supernatant protein 6 concentrations determined as described (McKie et al., 2000). 20-50 µg of cellular protein was 7 separated on a 10% Tris-Glycine polyacrylamide gel under reducing conditions andblotted to 8 nitrocellulose as described (Öhrvik et al., 2007). Three nitrocellulose membranes with 9 proteins from each T75 flasks were incubated in blocking buffer (5% nonfat dry milk powder 10 in Tris buffered saline containing 0.05% Tween 20 (TBS-T) over night at 4°C. Membranes 11 were then hybridized with a primary BCRP antibody (BXP-53, Abcam) diluted 1:100 or 12 primary MDR1 antibody (JSB-1, Abcam) diluted 1:200 in TBS-T. The primary antibodies 13 were detected by Horse Radish Peroxidase-conjugated secondary antibodies (ab6728, Abcam) 14 diluted 1:7500 in TBS-T. In order to normalize the intensities of the bands, all the membranes 15 were stripped at 60°C with buffer containing 62.5 mM Tris-HCl, 100 mM 2-mercaptoethanol, 16 2% SDS and then hybridized with anti-Tubulin antibody (YOL1/34) diluted 1:3000. Horse 17 Radish Peroxidase-conjugated secondary antibodies to tubulin (ab6734, Abcam) diluted 18 1:5000 in TBS-T. HRP was detected by ECL Advance (GE Healthcare) and the intensities of 19 the obtained bands quantitated as described (Öhrvik et al. 2010). As a quality control of the 20 antibodies used in the Western with cellular protein, they were tested on protein isolated from 21 mammary gland of pregnant and lactating mice.

22

23 Bcrp RNAi

24 Prior to the *Bcrp* RNAi of the HC11 cells optimization of transfection efficiency was

25 performed by incubating various densities of HC11 cells with either siTOX Transfection

1 Control (Dharmacon) or a non-targeting negative control (On-Target plus siControl Non-2 Targeting Pool, Dharmacon) in the presence of various dilutions of DharmaFECT siRNA 3 Transfection Reagents 1-4, as recommended by the manufacturer (Dharmacon). ATP levels 4 were measured to check viability of the HC11 cells following each set of transfection 5 condition by applying the ATP Determination Kit (Invitrogen), with formaldehyde-treated 6 cells as positive controls. Firefly luciferase induced chemiluminescence of cellular ATP was measured on a Victor² 1420 multilabel counter (PerkinElmer). Following the various 7 8 transfection conditions the one resulting in the lowest viability following treatment with 9 siTOX Transfection Control reagent and the highest viability following treatment with the 10 On-Target plus siControl Non-Targeting Pool was selected. Following this optimization of 11 transfection efficiency cyclophilin B siRNA transfection was performed under the optimized 12 condition by the use of siControl cyclophilin B siRNA (targeting mouse cyclophilin, 13 accession number NM_011149) according to the instructions of the manufacturer. The 14 silencing of the cyclophilin B gene was measured by quantitative real-time RT-PCR with 15 specific primers (Table 1) as described above. After successful silencing of cyclophilin B the 16 optimized siRNA transfection protocol was adopted to silence Bcrp expression. HC11 cells 17 were harvested in antibiotic-free RPMI 1640 medium and seeded into 6-well tissue culture plates at a density of 8,300 cells/cm². After incubation for 24 h at 37°C the medium was 18 19 replaced with 2 ml of transfection medium (Opti-MEM) containing 100 nM On-Target plus 20 SMART pool (targeting mouse BCRP, accession number NM_011920) and DharmaFECT 1 21 Transfection Reagent diluted 1:4. Mock transfected cells were incubated as described above 22 with 2 ml Opti-MEM containing 100 nM On-Target plus siControl Non-Targeting RNA 23 duplexes. Following transfection for 48 h at 37°C the HC11 cells were either subjected to 24 RNA isolation for quantitative gene expression of *Bcrp* by real-time RT-PCR or transport 25 experiments with MX (as described below).

2 Transport experiments

3 Prior to the experiments HC11 cells were seeded in 12 well plates at a density of 50,000 cells/cm² and cultured and treated as described above. MX (Sigma) was used to examine the 4 function of BCRP in the HC11 cells using ³H-MX, with a specific radioactivity of 4 Ci/mmol, 5 6 as tracer (Moravek Biochemicals). It has previously been demonstrated that BCRP mediated 7 transport of MX is reduced by GF120918 (de Bruin et al., 1999). Accumulation studies with 8 MX were performed as follows. HC11 cells were rinsed with 2 x 1.5 ml of 37°C Hank's 9 Balanced Salt Solution with CaCl2 and MgCl2 (Invitrogen), pH 7.4 containing 25 mM N-(2-10 hydroxyehtyl) piperazine-N'-(2-ethanesulfonic) acid (HEPES, Sigma-Aldrich) (HBSS) and 11 then pre-incubated for 30 min at 37° in 1.5 ml HBSS. After pre-incubation the HC11 cells 12 were incubated at 37°C for 60 min with 37°C HBSS containing 1 µM MX supplemented 3000 Bq ³H-MX/ml. Experiments including inhibitor were performed in HBSS, containing 1 μ M of 13 14 GF120918 during the 60 min incubation period. At the end of the experiment the HC11-cells 15 were rinsed with 3 x 1.5 ml ice-cold HBSS and thereafter lysed by adding 1 ml 0.5 M NaOH 16 to each well. The MX concentration in the HC11 cells was then calculated from the radioactivity measurement by β-spectrometry using a 1900 CA Tri-Carb[®]Liquid Scintillation 17 18 Analyzer (Packard Instruments). An aliquot of the cell lysate was used for protein 19 determination by applying the BCA-method (as described above).

20

To study secretion of MX HC11 cells were preincubated as described above and then
incubated with 1 µM MX supplemented 3000 Bq ³H-MX/ml at 37°C for 60 min. After this
loading period the incubation medium was discarded and the HC11 cells were rinsed with 2 x
1.5 ml 37°C HBSS. After the washes 1.5 ml of 37°C HBSS with or without 1 µM GF120918
was added to the wells followed by incubation at 37°C for 45 min. At the end of the secretion

1 experiment the HBSS was sampled and MX concentrations measured by β -spectrometry as 2 described above. Both accumulation and secretion of MX was normalized to total cellular 3 protein of the HC11 cells. Prior to the transport experiments potential cellular toxicity of the 4 MX and GF120918 was assessed by measuring cellular ATP levels as described above or 5 leakage of lactate dehydrogenase (LDH) as described previously (Aspenström-Fagerlund et 6 al., 2007). No effects in ATP- or LDH-levels were detected in the experimental conditions 7 and MX and GF120918 concentrations used in the present study indicating that the observed effects in accumulation and secretion were not a result of cytotoxicity induced by of these 8 9 chemical compounds.

10

11 Statistics

12 Statistical analysis was performed using Statview 4.1 software for PC. Kruskal-Wallis was 13 used to detect any significant differences in the data. Mann-Whitney was applied to examine 14 statistically significant differences between two groups. The level of significance was set at p 15 ≤ 0.05 .

1 Results

2

3 *Cellular organization*

The morphology of the HC11 cells was affected by the differentiation procedure. The
differentiated cells showed a characteristic pattern with alveolar resembling structures
including lumina, whereas the undifferentiated cells were organized as a monolayer (Figure
1).

8

9 mRNA expressions

10 Gene expression of β -casein (*Csn2*) and *Bcrp* was detected in both undifferentiated and

11 differentiated HC11 cells. A statistically significant induction of β -casein gene expression

12 was observed in the differentiated HC11 cells as compared to the undifferentiated controls

13 (Figure 1a). Thus, the relative β -casein gene expression was increased 2-fold in the

14 differentiated as compared to the undifferentiated HC11 cells (Figure 1a). The relative *Bcrp*

15 gene expression was at a similar level in undifferentiated and differentiated HC11 cells

16 (Figure 2a). A statistically significant 2-fold reduction in *Mdr1* gene expression was observed

17 in the differentiated HC11 as compared to the undifferentiated ones (Figure 2b).

18

19 Protein expressions

20 Bcrp and Mdr1-protein was detected in both undifferentiated and differentiated HC11 cells

21 (Figure 3). Tubulin normalized Bcrp protein expression was up-regulated and Mdr1 protein

22 expression down-regulated in the differentiated as compared to the undifferentiated HC11

23 cells (Figure 3). Quantification of Bcrp and Mdr1 protein levels in differentiated and

24 undifferentiated HC11 cells as performed in two separate experiments with triplicate analyses

25 did not show any overlaps in protein levels.

2 Bcrp silencing

To test the function of our optimized transfection efficiency conditions RNAi was initially performed with the house-keeping gene cyclophilin B. Our results showed that almost a 90% down-regulation of the cyclophilin B gene expression was obtained (Figure 4). Using the same protocol with *Bcrp* siRNA-duplexes *Bcrp*-transcript levels were reduced to the same extent as cyclophilin (Figure 4).

8

9 Transport experiments

The transport experiments with ³H-MX showed that the accumulation was increased in both 10 11 undifferentiated and differentiated HC11 cells simultaneously incubated with GF120918 12 (Figure 5a). Thus, in the presence of the BCRP inhibitor the accumulation of MX increased 13 with about 21% in the undifferentiated HC11 cells and with about 36% in the differentiated 14 ones. Our results also showed that the accumulation of MX was higher in the differentiated 15 HC11 cells as compared to the undifferentiated controls (Figure 5a). The presence of the 16 inhibitor GF120918 also resulted in a decreased secretion of MX from the loaded HC11 cells 17 (Figure 5b). The secretion of MX was reduced to about 65% in the presence of GF120918 in 18 undifferentiated HC11 cells and to about 70% in the differentiated ones. The results obtained 19 in the transport experiments with ³H-MX showed that the accumulation of MX in HC11 cells 20 increased 2-fold by Bcrp RNAi as compared to the MX accumulation in the mock transfected 21 HC11 cells (Figure 5a).

1 Discussion

2

3 The results obtained in the present investigation demonstrate for the first time that both Bcrp 4 and Mdr1 are expressed in the HC11 cells and are up- and downregulated, respectively by 5 differentiation as in mammary epithelial cells in vivo during lactation. Thus, whereas Bcrp 6 protein levels were increased in HC11 cells differentiated into a secreting phenotype, Mdr1 7 protein levels were decreased. These results are in line with the *in vivo* findings that BCRP is 8 up-regulated and MDR1 down-regulated in lactating mammary glands in various species 9 (Alcorn et al., 2002; Jonker et al., 2005; Gilchrist and Alcorn, 2009) and suggest that the 10 HC11 model can be used to both assess function of endogenous Bcrp and to detect new 11 substrates as well as inducers and inhibitors of this transporter.

12

13 HC11 cells have been used as a model for studies on hormonal regulation of mammary 14 epithelial cell differentiation as well as milk protein gene expression and secretion (Wartmann 15 et al., 1996; Desrivières et al., 2003; Kabotyanski et al., 2006). Furthermore, HC11 cells have 16 been applied to examine the impact of toxic compounds on lactating mammary cells (Öhrvik 17 et al., 2010) and also to characterize some transporters belonging to the Solute Carrier (SLC) 18 family and ion channels, which are implicated in the flux of magnesium, zinc, copper and 19 calcium across the membranes of the lactating mammary epithelium (Kelleher and Lönnerdal, 20 2005, 2006; Boyd and Náray-Fejes-Tóth, 2007; Öhrvik et al, 2010; Wolf et al., 2010; 21 McCormick and Kelleher, 2012; Ross et al., 2013). However, the HC11 cell model has not yet 22 been used to characterize expression and/or function of ATP Binding Cassette (ABC) 23 transporters. The localization of both BCRP and MDR1 in the apical membranes of MECs in 24 combination with the promiscuity of these active transporters has risen considerable concern 25 from public health, food safety, and regulatory perspectives about the presence of drugs and

toxic compounds in milk both for breast fed infants as well as for consumers of dairy products
 (Wassermann et al., 2013).

3

4 Herein, we showed that *Bcrp* gene expression was at a similar level in undifferentiated and 5 differentiated HC11 cells whereas *Mdr1* transcript levels were reduced in the differentiated 6 ones. The reason for the lack of induction of *Bcrp* mRNA in the HC11 cells by lactogenic 7 stimulation in the present investigation is unknown. However, one possible explanation may 8 be that the HC11 cells originally derive from mammary tissue of BALB/c mice during 9 gestation when *Bcrp* transcripts levels are induced to a stage where no further increases in 10 gene expression occurs (Danielsson et al., 1984; Jonker et al., 2005). In support of this, 11 silencing of *Bcrp* gene expression in undifferentiated HC11 cells resulted in a marked 12 decrease in Bcrp function as assessed by increased MX accumulation, which probably would 13 not have been possible to demonstrate if the endogenous Bcrp expression in the control cells 14 was at a baseline level.

15

16 In the present investigation the HC11 cells differentiated by treatment with prolactin and 17 cortisol were organized into alveolar-like structures with lumina resembling the organization 18 of the mammary epithelial cells observed in the mammary glands in vivo during lactation 19 (Burgoyne and Duncan, 1998; Richert et al., 2000).. Beside the changes in cellular 20 organization by lactogenic stimulation β -casein gene expression was also induced in the 21 HC11 cells. It has previously been demonstrated that β -case in responds to prolactin in HC11 22 cells (Ball et al., 1988) and that synthesis occurs in rodent MEC in vivo and that the 23 abundance of this milk protein increases during gestation and peaks at mid-lactation 24 (Robinson et al., 1995; Burgoyne and Duncan, 1998; Richert et al., 2000; McManaman and 25 Neville, 2003). Thus, reorganization of HC11 cells into alveolar-resembling formations in

combination with an increased β-casein gene expression by lactogenic stimulation appears to
 be reliable markers of a secreting phenotype. Based on the results obtained in the present
 study reduced gene and protein expression of Mdr1 as well as increased expression of Bcrp
 protein may also be used as secretory markers of the HC11 cells.

5

6 Our results showed that the net accumulation of MX was higher in the differentiated HC11 7 cells as compared to the undifferentiated controls despite an apparent higher expression of 8 Bcrp. This may, at least in part, be explained by a reduced expression of Mdr1. Although MX 9 extrusion is predominantly mediated by Bcrp it has been demonstrated that MX can be 10 transported to the extracellular compartment by Mdr1 although this transporter harbors less 11 substrate specificity for MX than Bcrp and thus requires higher substrate concentrations 12 (Ahmed-Belkacem, 2005; Rautio et al., 2006; Kodaira et al., 2010). Numerous SLC 13 transporters, comprising both organic cation transporters (OCTs) and organic anion 14 polypeptide transporters (OATPs), in MECs are affected at the transcriptional level by 15 lactogenic stimulation (Alcorn et al., 2002; Gilchrist and Alcorn, 2010) including some with 16 potential MX affinity. It may, hence, be possible that the increased accumulation of MX in the 17 HC11 cells featuring a secretory phenotype as opposed to the undifferentiated ones is not only 18 connected to the reduced expression of Mdr1 observed herein, but also to a concerted action 19 of a number of other transporters including Oct or/and Oatp transporters.

20

Madine-Darby Canine Kidney II (MDCK II), human intestinal epithelial cells (Caco-2),
human breast adenocarcinoma cells (MCF7), human choriocarcinoma cells (BeWo) and
human bone osteosarcoma cells (SAOS-2) constitute examples of models used to characterize
the function and substrate specificities of efflux proteins such as BCRP (Doyle et al., 1998;
Jonker et al., 2000; Ceckova et al., 2006; Matsson et al., 2007; Li et al., 2011; Wasserman et

1	al., 2013). However, cancer cell lines and non-tumorigenic cell lines deriving from tissues
2	other than the alveolar lining of the mammary glands harbor different sets of transporter
3	protein panels at both the apical and basolateral membranes which may affect secretion and
4	net accumulation of substrates may therefore differ (Krajci 2013). As expected by a Bcrp
5	inhibitor, GF120918 treatment of HC11 cells decreased both net accumulation and secretion
6	of MX. This corroborates our suggestion that the HC11 cells can be used for assessing
7	transport of potential Bcrp substrates across the mammary epithelium.
8	
9	The results obtained in the present investigation demonstrate for the first time that the murine
10	mammary epithelial HC11 cells feature endogenous Bcrp and Mdr1 expression and that the
11	expressions of these transporter proteins appear to respond to treatment with lactogenic
12	hormones in a corresponding manner as mammary epithelial cells in vivo during lactation.
13	Based on these findings it can be concluded that the HC11cells comprise a promising tool to
14	assess the impact of drugs and other chemicals on endogenous BCRP function.
15	
16	

1 Acknowledgements

- 2 This study was supported by the Swedish Research Council for Environment, Agricultural
- 3 Sciences and Spatial Planning (Formas).
- 4

5 **Conflict of Interest**

- 6 There are no conflicts of interest regarding this manuscript and the authors have nothing to
- 7 disclose.
- 8

\mathbf{a}
,

Ahmed-Belkacem A, Pozza A, Munoz-Martinez F, Bates SE, Castanys S, Gamarro F et al.
Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and
specific inhibitors of breast cancer resistance protein ABCG2. Cancer Res 2005;65:4852-60.
Alcorn J, Lu X, Moscow A, McNamara PJ. Transporter gene expression in lactating and
nonlactating human mammary epithelial cells using real-time reverse transcription-
polymerase chain reaction. J Pharmacol Exp Ther 2002;303:487-96.
Aspenström-Fagerlund B, Ring L, Aspenström P, Tallkvist J, Ilbäck NG, Glynn A. Oleic acid
and docosahexanoic acid cause an increase in the paracellular absorption of hydrophilic
compounds in an experimental model of human absorptive enterocytes. Toxicology
2007;237:12-23.
Ball RK, Friis RR, Schoenenberger CA, Doppler W, Groner B. Prolactin regulation of β -
casein gene expression and of a cytosolic 120-kd protein in a cloned mouse mammary
epithelial cell line. Embo J 1988;7:2089-95.
Bates SE, Robey R, Miyake K, Rao K, Ross DD, Litman T. The role of half-transporters in
multidrug resistance. J Bioenerg Biomembr 2001;33:503-11.
Boyd C, Náray-Fejes-Tóth A. Steroid-mediated regulation of the epithelial sodium channel
subunits in mammary epithelial cells. Endocrinology 2007;148:3958-67.

2	1998;3:275-86.
3	
4	Ceckova M, Libra A, Pavek P, Nachtigal P, Brabec M, Fuchs R et al. Expression and
5	functional activity of breast cancer resistance protein (BCRP/ABCG2) transporter in the
6	human choriocarcinoma cell line BeWo. Clin Exp Pharmacol Physiol 2006;33:58-65.
7	
8	Danielsson KG, Oborn CJ, Durban EM, Butel JS, Medina D. Epithelial mouse mammary cell
9	line exhibiting normal morphogenesis in vivo and functional differentiation in vitro. PNAS
10	1984;81:3756-60.
11 12	de Bruin M, Miyake K, Litman T, Robey R, Bates SE. Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Lett 1999;146:117-28.
13	Desrivières S, Prinz T, Castro-Palomino Laria N, Meyer M, Boehm G, Bauer U et al.
14	Comparative proteomic analysis of proliferating and functionally differentiated mammary
15	epithelial cells. Mol Cell Proteomics 2003;2:1039-54.
16	
17	Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK et al. A multidrug
18	resistance transporter from human MCF-7 breast cancer cells. PNAS USA 1998;95:15665-70.
19	
20	Gilchrist SE, Alcorn J. Lactation stage-dependent expression of transporters in rat whole
21	mammary gland and primary mammary epithelial organoids. Fundam Clin Pharmacol
22	2010;24:205-14.

Burgoyne RD, Duncan JS. Secretion of milk proteins. J Mammary Gland Biol Neoplasia

1	Halwachs S, Wassermann L, Lindner S, Zizzadoro C, Honscha W. Fungicide prochloraz and
2	environmental pollutant dioxin induce the ABCG2 transporter in bovine mammary epithelial
3	cells by the arylhydrocarbon receptor signalling pathway. Toxicol Sci 2013;131:491-501.
4	
5	Halwachs S, Wassermann L, Honscha W. A novel MDCKII in vitro model for assessing
6	ABCG2 transport activity in the caprine mammary gland by environmental pollutants and
7	pesticides. Toxicol In Vitro 2014;28:432-41.
8	
9	Jonker JW, Smit JW, Brinkhuis RF, Maliepard M, Beijnen JH, Schellens JH et al. Role of
10	breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl
11	Cancer Inst 2000;92:1651-6.
12	
13	Jonker JW, Merino G, Musters S, Herwaarden AE, Bolscher E, Wagenaar E et al. The breast
14	cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins
15	into milk. Nat Med 2005;11:127-29.
16	
17	Kabotyanski EB, Huetter M, Xian W, Rijnkels M, Rosen JM. Integration of prolactin and
18	glucocorticoid signalling at the beta-casein promoter and enhancer by ordered recruitment of
19	specific transcription factors and chromatin modifiers. Mol Endocrinol 2006;20:2355-68.
20	
21	Kelleher SL, Lönnerdal B. Zip3 plays a major role in zinc uptake into mammary epithelial
22	cells and is regulated by prolactin. Am J Physiol Cell Physiol 2005;288:1042-47.
23	

1	Kelleher SL, Lönnerdal B. Mammary gland copper transport is stimulated by prolactin
2	through alterations in Ctr1 and Atp7A localization. Am J Physiol Regul Integr Comp Physiol
3	2006;291:1181-91.
4	
5	Kodaira H, Kusuhara H, Ushiki J, Fuse E, Sugiyama Y. Kinetic analysis of the cooperation of
6	P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting
7	the brain and testis penetration of erlotinib, flavopiridol and mitoxantrone. J Pharmacol Exp
8	Ther 2010;333:788-96.
9	
10	Krajci P. Drug-transporter interaction testing in drug discovery and development. World J
11	Pharmacol 2013;2:35-46.
12	
13	
14	Li J, Volpe DA, Wang Y, Zhang W, Bode C, Owen A et al. Use of transporter knockdown
15	Caco-2 cells to investigate the in vitro efflux of statin drugs. Drug Metab Dispos
16	2011;39:1196-202.
17	
18	Lindner S, Halwachs S, Wassermann L, Honscha W. Expression and subcellular localization
19	of efflux transporter ABCG2/BCRP in important tissue barriers of lactating dairy cows, sheep
20	and goats. J Vet Pharmacol Ther 2013;36-562-70.
21	
22	Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH et
23	al. Subcellular localization and distribution of the breast cancer resistance protein transporter
24	in normal human tissues. Cancer Res 2001;61:3458-64.
25	

1	Marte BM, Meyer T, Stabel S, Standke GIR, Jaken S, Fabbro D et al. Protein kinase C and
2	mammary cell differentiation: involvement of protein kinase C alpha in the induction of beta-
3	casein expression. Cell Growth Differ 1994;5:239-47.
4	
5	Matsson P, Englund G, Ahlin G, Bergström CAS, Norinder U, Artursson P. A global drug
6	inhibiton pattern for the human ATP-binding cassette transporter breast cancer resistance
7	protein (ABCG2). J Pharmacol Exp Ther 2007;323:19-30.
8	
9	McCormick NH, Kelleher SL. ZnT4 provides zinc to zinc-dependent proteins in the trans-
10	Golgi network critical for cell function and Zn export in mammary epithelial cells. Am J
11	Physiol Cell Physiol 2012;303:291-7.
12	
13	McKie AT, Marciani P, Rolfs A, Brennan K, Wehr K, Barrow D et al. A novel duodenal iron-
14	regulated transporter, IREG, implicated in the basolateral transfer of iron to the circulation.
15	Mol Cell 2000;5:299-309.
16	
17	McManaman JL, Neville MC. Mammary physiology and milk secretion. Adv Drug Deliv Rev
18	2003;55:629-41.
19	
20	Mealey KL. ABCG2 transporter: therapeutic and physiologic implications in veterinary
21	species. J Vet Pharmacol Therap 2012;35:105-12.
22	
23	Morris ME, Zhang S. Flavonoid – drug interactions: Effects of flavonoid on ABC
24	transporters. Life Sci 2006; 78; 2116-30.
25	

1	Rautio J, Humphreys JE, Webster LO, Balakrishnan A, Keogh JP, Kunta JR et al. In vitro p-
2	glycoprotein inhibition assays for assessment of clinical drug interaction potential of new
3	drug candidates: a recommendation for probe substrates. Drug Metab Dispos 2006;34:786-92.
4	
5	Real R, González-Lobato L, Baro MF, Valbuena S, de la Fuente A, Prieto JG et al. Analysis
6	of the effect of the bovine adenosine triphosphate-binding cassette transporter G2 single
7	nucleotide polymorphism Y581S on transcellular transport of veterinary drugs using new cell
8	culture models. J Anim Sci 2011;89:4325-38.
9	
10	Richert MM, Schwertfeger KL, Ryder JW, Anderson SM. An atlas of mouse mammary gland
11	development. J Mammary Gland Biol Neoplasia 2000;5:227-241.
12	
13	Robinson GW, McKnight RA, Smith GH, Hennighausen L. Mammary epithelial cells
14	undergo secretory differentiation in cycling virgins but require pregnancy for the
15	establishment of terminal differentiation. Development 1995;121:2079-90.
16	
17	Ross DG, Smart CE, Azimi I, Roberts-Thomson SJ, Monteith GR. Assessment of ORAI1-
18	mediated basal calcium influx in mammary epithelial cells. BMC Cell Biol 2013;14:57.
19	Doi: 10.11186/1471-2121-14-57.
20	
21	van Herwaarden AE, Wagenaar E, Merino G, Jonker JW, Rosing H, Beijnen JH et al.
22	Multidrug transporter ABCG2/breast cancer resistance protein secretes riboflavin (vitamin
23	B2) into milk. Mol Cell Biol 2007;27:1247-53.

1	Vlaming MLH, Lagas JS, Schinkel AH. Physiological and pharmacological roles of
2	ABCG2(BCRP): recent findings in Abcg2 knockout mice. Adv Drug Deliv Rev 2009;61:14-
3	25.
4	
5	Wartmann M, Cella N, Hofer P, Groner B, Liu X, Hennighausen L et al. Lactogenic hormone
6	activation of Stat5 and transcription of the beta-casein gene in mammary epithelial cells is
7	independent of p42 ERK mitogen-activated protein kinase activity. J Biol Chem
8	1996;271:31863-68.
9	
10	Wassermann L, Halwachs S, Baumann D, Schaefer I, Seibel P, Honscha W. Assessment of
11	ABCG2-mediated transport of xenobiotics across the blood-milk barrier of dairy animals
12	using a new MDCKII in vitro model. Arch Toxicol 2013;87:1671-82.
13	
14	Wolf FI, Trapani V, Simonacci M, Mastrototaro L, Cittadini A, Schweigel M. Modulation of
15	TRPM6 and $Na(+)/Mg(2+)$ exchange in mammary epithelial cells in response to variations of
16	magnesium availability. J Cell Physiol 2010; 222:374-81.
17	
18	Zhang S, Yang X, Morris ME. Flavonoids are inhibitors of breast cancer resistence protein
19	(ABCG2)-mediated transport. Mol Pharmacol 2004;65:1208-16.
20	
21	Öhrvik H, Oskarsson A, Lundh T, Skerfving S, Tallkvist J. Impact of iron status on cadmium
22	uptake in suckling piglets. Toxicology 2007;240:15-24.
23	

- 1 Öhrvik H, Ullerås E, Oskarsson A, Tallkvist J. Effects of cadmium on calcium transporter
- 2 SPCA, calcium homeostasis and beta-casein expression in the murine mammary epithelium.
- 3 Tox Lett 2010;201:80-85.
- 4
- 5

- **Table 1.** Exon-spanning oligonucleotide primers used for quantitative gene expression
- 2 analyses by real-time RT-PCR.

Gene	Primer Sequences
β-casein	5'-CTTAACCCCACCGTCCAAT-3' (forward)
	5'-AGCATGATCCAAAGGTGAAAA-3' (reverse)
Bcrp/Abcg2	5'-CGCAGAAGGAGATGTGTT-3' (forward)
	5'-TTGGATCTTTCCTTGCTGCT-3' (reverse)
Mdr1/Abcb1	5'-GCTGTTAAGGAAGCCAATGC-3' (forward)
	5'-AGCAATGGCGATTCTCTGGTT-3' (reverse)
Cyclophilin B	5'-GCGCAATATGAAGGTGCTCT-3' (forward)
	5'-GAAGTCTCCACCCTGGATCA-3' (reverse)

1 Legends to the figures


2

3 Figure 1. a. Cellular organization of undifferentiated and differentiated HC11 cells as 4 described in Materials and Methods. Undifferentiated HC11 cells not stimulated with 5 lactogenic hormones are organized as monolayers (left). Differentiated cells treated with 6 prolactin and hydrocortisone are formatted in alveolar-resembling structures with alveolar 7 lumina (right). b. Relative β -casein gene expression in undifferentiated and differentiated 8 HC11 cells, as described in Materials and Methods. The data are presented as means \pm SD of 9 6 samples from 2 separate experiments. *Statistically significant different as compared to 10 undifferentiated controls, $p \le 0.05$. 11 12 Figure 2. Relative gene expression of *Bcrp* (a) and *Mdr1* (b) in undifferentiated and 13 differentiated HC11 cells, as described in Materials and Methods. The data are presented as means ± SD of 6 samples from 2 separate experiments. *Statistically significant different as 14 15 compared to undifferentiated controls $p \le 0.05$. 16 17 Figure 3. Protein expression of BCRP (a) and MDR1 (b) in undifferentiated and 18 differentiated HC11 cells, normalized to tubulin expression as described in Materials and 19 Methods. The data represent BCRP and MDR1 protein expression in HC11 cell lysates 20 obtained in two separate experiments, each comprising three membranes per protein 21 expressed as relative means and ranges. 22 23 Figure 4. Relative gene expressions of cyclophilin B and *Bcrp* in HC11 cells subjected to 24 RNA interference (RNAi). The data are presented as means \pm SD of 3-5 samples obtained from 2 separate experiments. *Statistically significant as compared to untransfected controls 25


- (Opti-MEM) and mock transfected cells (Opti-MEM containing Lipid 1 diluted 1:4 and non targeting RNA duplexes) as described in Materials and Methods, p ≤ 0.05.

Figure 5. Accumulation (a) and secretion (b) of ³H-mitoxantrone in undifferentiated (No) or, differentiated (Yes) HC11 cells, treated with the BCRP inhibitor GF120918, and in mock transfected (mock) and *Bcrp* RNAi treated (Bcrp RNAi) HC11 cells, as described in Material and Methods. The data are presented as means \pm SD of 6-12 samples and expressed as pmol mitoxantrone/mg cellular protein as described in Materials and Methods. Statistically significant differences between groups are indicated by links between the columns (*p \leq 0.05; ** $p \le 0.01$).


- **Figure 1.**




- **Figure 2.**




- **Figure 3.**



- **Figure 4.**





b

